Recent developments include the closing of a strategic acquisition of dual-targeting CAR-T assets, securing up to $6 million in funding to advance the clinical pipeline, insider buying activity, and regulatory milestones such as NMPA approval for a pivotal trial in China.

• Tempest completed the acquisition of dual-targeting CAR-T assets in February 2026, issuing 8,268,495 shares to the sellers, expanding its pipeline with programs including TPST-2003 for multiple myeloma [N3][S1].
• The company secured up to $6 million in funding to advance its clinical pipeline in March 2026, though the stock price declined following the announcement [N2].
• Insider buying was reported in March 2026, indicating potential confidence from company insiders [N1].
• Tempest announced a record date for anticipated dividend distribution of warrants to stockholders in January 2026 [N4].
• Regulatory progress includes receiving NMPA approval for a pivotal trial of amezalpat in hepatocellular carcinoma treatment in China as of June 2025 [N5].
• The company completed a $4.6 million registered direct offering with an institutional investor in June 2025 [N6].
• Amezalpat received Orphan Drug Designation from the European Medicines Agency in June 2025 [N7].
• The company reported a net loss of $10.86 million in Q1 2025, reflecting ongoing investment in clinical development [N8].

Tempest Therapeutics has developed a diversified pipeline of innovative dual-targeting CAR-T therapies and first-in-class small molecule candidates addressing significant unmet medical needs in oncology and immunology. Early clinical data for TPST-2003 show promising efficacy and manageable safety in relapsed or refractory multiple myeloma. Regulatory designations for amezalpat and TPST-1495 provide potential development and market advantages. The company’s capital-efficient strategy leveraging partnerships and external funding supports parallel advancement of multiple programs. The strategic acquisition of CAR-T assets expands the pipeline and potential indications, positioning Tempest to address tumor heterogeneity and improve patient access through scalable manufacturing approaches.

Tempest Therapeutics faces significant risks inherent to clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes and regulatory approvals for its CAR-T and small molecule candidates. The early clinical data are limited in patient numbers and require further validation. The company’s capital resources are limited, with a net loss of $26.3 million in 2025 and modest cash reserves, necessitating continued external funding and partnerships. Competition from larger pharmaceutical and biotech companies with greater resources and alternative therapies may limit market opportunities. Manufacturing reliance on third parties and the complexity of CAR-T therapies add operational risks. Regulatory, safety, and commercial challenges could impede successful product development and commercialization.

Tempest Therapeutics' moat is based on its proprietary dual-targeting CAR-T cell therapy architecture, which aims to address tumor heterogeneity and antigen escape by simultaneously targeting two antigens, such as CD19 and BCMA in multiple myeloma. This approach may offer advantages over single-target CAR-T therapies in terms of durability and depth of response. Additionally, the company’s small molecule candidates, including amezalpat as a first-in-class selective PPARα antagonist and TPST-1495 as a dual EP2/EP4 antagonist, represent novel mechanisms of action with regulatory orphan drug designations that may provide market exclusivity benefits. The strategic acquisition of CAR-T assets and partnerships for clinical development further support its competitive positioning. However, the company operates in a highly competitive and rapidly evolving biotech landscape with larger players and multiple alternative therapies.

• Clinical Development Risk: The company’s product candidates are in early clinical stages with limited patient data; clinical trials may not demonstrate safety or efficacy sufficient for regulatory approval.
• Financial Risk: Net losses and limited cash reserves require ongoing capital raises and partnerships to fund development, which may dilute existing shareholders or constrain operations.
• Competitive Risk: The biotechnology and pharmaceutical sectors are highly competitive with many companies developing similar therapies, potentially limiting market share and pricing power.
• Manufacturing and Operational Risk: Dependence on third-party manufacturers for product supply introduces risks related to quality, capacity, and regulatory compliance.
• Regulatory Risk: Product candidates must navigate complex regulatory pathways; failure to obtain or maintain approvals could delay or prevent commercialization.

• Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates focused on oncology and immunology indications.
• In February 2026, Tempest completed a strategic acquisition of dual-targeting CAR-T assets, including TPST-2003, an autologous CD19/BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma (rrMM).
• The company’s CAR-T portfolio includes autologous, allogeneic, and in vivo dual-targeting CAR-T therapies targeting hematologic malignancies, solid tumors, and immunology indications.
• TPST-2003 is the lead autologous dual-targeting CAR-T candidate targeting CD19 and BCMA for rrMM, currently in Phase 1/2a clinical trials with 36 patients treated as of January 31, 2026, showing a 100% overall response rate in 25 evaluable patients.
• The safety profile of TPST-2003 includes no Grade 3 or higher cytokine release syndrome and limited neurotoxicity, supporting further clinical development.
• Other CAR-T candidates include TPST-2206 (dual-targeting CD70/CD70 for solid tumors), TPST-3003 and TPST-3206 (allogeneic dual-targeting CAR-Ts), and TPST-4003 (in vivo dual-targeting CAR-T for lupus).
• The small molecule pipeline includes amezalpat (formerly TPST-1120), a selective oral PPARα antagonist for first-line hepatocellular carcinoma (HCC), which completed Phase 2 with positive survival data and is Phase 3-ready with regulatory alignment.
• Amezalpat has received FDA Orphan Drug Designation and Fast Track Designation, as well as EMA Orphan Drug Designation for HCC.
• TPST-1495 is a dual antagonist of EP2 and EP4 receptors of prostaglandin E2, targeting familial adenomatous polyposis (FAP), with a planned NCI-funded Phase 2 trial expected to start in 2026.
• The company pursues a capital-efficient development strategy, leveraging partner support and external funding to advance multiple programs in parallel while managing internal cash resources.
• Manufacturing is outsourced to third parties with internal oversight; no owned manufacturing facilities currently.
• Competition includes large pharmaceutical and biotech companies developing CAR-T therapies and small molecules for similar indications; Tempest’s dual-targeting CAR-T and first-in-class small molecules provide differentiation.
• Financial snapshot as of December 31, 2025, shows cash and equivalents of $7.7 million, current assets of $8.3 million, current liabilities of $3.3 million, a current ratio of 2.5, and a net loss of $26.3 million for the fiscal year, with basic and diluted EPS of -$6.33 [S1].
• Recent developments include closing the strategic acquisition of dual-targeting CAR-T assets in February 2026 [N3][S1], securing up to $6 million to advance the clinical pipeline in March 2026 [N2], and insider buying reported in March 2026 [N1].
• The company announced a record date for anticipated dividend distribution of warrants to stockholders in January 2026 [N4].
• Regulatory milestones include NMPA approval for pivotal trial of amezalpat in China in June 2025 [N5].
• The company completed a $4.6 million registered direct offering with an institutional investor in June 2025 [N6].
• Orphan Drug Designations for amezalpat and TPST-1495 were granted by FDA and EMA in 2025 [N7][N1].